AMGOMED

THROMBOMAX 12MIU/1.5mg

Recombinant Human Interleukin 11Thrombopoietic Growth Factor
Sterile Lyophilized powder for Injection

Thrombomax (IL-11) is a new treatment option which is FDA approved & now available in Pakistan for Thrombocytopenic patients.

Thrombomax, Interleukin eleven (IL-11) is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. IL-11 is a member of a family of human growth factors. Oprelvekin, the active ingredient in Thrombomax, is produced in Escherichia coli (E. coli) by recombinant DNA technology. Trials have shown that mature megakaryocytes which develop during in vivo treatment with Thrombomax are ultra-structurally normal and possessed a normal life span.

INDICATIONS:

Thrombomax is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with non-myeloid malignancies who are at high risk of severe thrombocytopenia. Efficacy was demonstrated in patients who had experienced severe thrombocytopenia following the previous chemotherapy cycle. Thrombomax is not indicated following myeloablative chemotherapy.

ADVANTAGES:

Mean time to platelet recovery to ≥20,000 cells/µL with rhIL-11 is at least 2.5 days vs 6.4 days for placebo patients. [3]
Mean time to platelet recovery to ≥ 50,000 cells/µL with rhIL-11 is at least 9.3 days vs 13.0 days with placebo. [3]

BRIEF PRESCRIBING INFORMATION:

Drug Description: Thrombomax IL-11 is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. It is a member of family of human growth factors. Oprelvekin, the active ingredient in Thrombomax, is produced in E.Coli by recombinant DNA technology. Indications: Prevention of thrombocytopenia and the reduction of the need for platelet transfusion following myelosuppressive chemotherapy in adult patients with non-myeloid malignancies who are at high risk of developing thrombocytopenia. Efficacy demonstrated in patients who had experienced severe thrombocytopenia following previous chemotherapy cycle. Dosage and Administration: Dissolve one vial with 1ml sterilized water for injection. Recommended dosage is 25-50µg/kg. Subcutaneously administer Rh.IL-11, 24-48 hours after the course of chemotherapy is over. The course is generally of 14-21 days. After the platelet count reached normal level, stop using Thrombomax Side Effects: Clinical studies showed that most of the side effects of Rh.IL-11 are slight or moderate and are relieved soon after stopping the treatment. About 10% patients experience debilitation, pain, shivering, and infection. General: headache & edema. CVS: Tachycardia & vasodilation. G.I: Dyspepsia, nausea & constipation. CNS: Dizziness and insomnia. Respiratory System: Dyspnea, rhinitis, cough, pharyngitis & pleural effusion. Others: Rash, conjunctival congestion, and occasionally blurred vision. Storage: Store between 2°-8° C.